CHROMADEX CORP (CDXC) Stock Fundamental Analysis
NASDAQ:CDXC - Nasdaq - US1710774076 - Common Stock - Currency: USD
Overall CDXC gets a fundamental rating of 5 out of 10. We evaluated CDXC against 56 industry peers in the Life Sciences Tools & Services industry. CDXC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CDXC shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year CDXC was profitable.
In the past year CDXC had a positive cash flow from operations.
In the past 5 years CDXC always reported negative net income.
In the past 5 years CDXC reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 2.63%, CDXC is doing good in the industry, outperforming 78.57% of the companies in the same industry.
CDXC's Return On Equity of 4.32% is fine compared to the rest of the industry. CDXC outperforms 76.79% of its industry peers.
The Return On Invested Capital of CDXC (0.91%) is better than 66.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.32% | ||
| ROIC | 0.91% |
ROA(3y)-28.83%
ROA(5y)-43.66%
ROE(3y)-53.52%
ROE(5y)-87.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 1.62%, CDXC is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
CDXC has a better Operating Margin (0.49%) than 62.50% of its industry peers.
CDXC has a Gross Margin of 61.45%. This is amongst the best in the industry. CDXC outperforms 87.50% of its industry peers.
CDXC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.49% | ||
| PM (TTM) | 1.62% | ||
| GM | 61.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.69%
GM growth 5Y3.61%
2. Health
2.1 Basic Checks
CDXC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, CDXC has more shares outstanding
Compared to 5 years ago, CDXC has more shares outstanding
The debt/assets ratio for CDXC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 8.91 indicates that CDXC is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.91, CDXC belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
CDXC has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.00, CDXC belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CDXC is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.00, CDXC belongs to the best of the industry, outperforming 80.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.91 |
ROIC/WACC0.08
WACC11.41%
2.3 Liquidity
A Current Ratio of 2.95 indicates that CDXC has no problem at all paying its short term obligations.
CDXC has a Current ratio (2.95) which is comparable to the rest of the industry.
CDXC has a Quick Ratio of 2.35. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CDXC (2.35) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.35 |
3. Growth
3.1 Past
CDXC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 111.11%, which is quite impressive.
CDXC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.94%.
CDXC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y12.14%
Revenue growth 5Y21.5%
Sales Q2Q%31.21%
3.2 Future
The Earnings Per Share is expected to grow by 64.82% on average over the next years. This is a very strong growth
Based on estimates for the next years, CDXC will show a quite strong growth in Revenue. The Revenue will grow by 17.67% on average per year.
EPS Next Y158.29%
EPS Next 2Y93.61%
EPS Next 3Y64.82%
EPS Next 5YN/A
Revenue Next Year16.58%
Revenue Next 2Y18.63%
Revenue Next 3Y17.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 542.00 indicates a quite expensive valuation of CDXC.
Compared to the rest of the industry, the Price/Earnings ratio of CDXC is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 29.62. CDXC is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 44.28 indicates a quite expensive valuation of CDXC.
CDXC's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.70. CDXC is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 542 | ||
| Fwd PE | 44.28 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CDXC.
The rest of the industry has a similar Price/Free Cash Flow ratio as CDXC.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 101.94 | ||
| EV/EBITDA | 295.93 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as CDXC's earnings are expected to grow with 64.82% in the coming years.
PEG (NY)3.42
PEG (5Y)N/A
EPS Next 2Y93.61%
EPS Next 3Y64.82%
5. Dividend
5.1 Amount
CDXC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.42
-0.28 (-4.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner Change-94.32%
Ins Owners0.01%
Ins Owner Change0.08%
Market Cap413.98M
Analysts84.44
Price Target7.85 (44.83%)
Short Float %4.3%
Short Ratio4.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)294.41%
Min EPS beat(2)100%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)182.5%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)109.88%
EPS beat(12)10
Avg EPS beat(12)76.36%
EPS beat(16)11
Avg EPS beat(16)52.63%
Revenue beat(2)1
Avg Revenue beat(2)0.6%
Min Revenue beat(2)-4.88%
Max Revenue beat(2)6.07%
Revenue beat(4)1
Avg Revenue beat(4)-2.29%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.07%
Revenue beat(8)3
Avg Revenue beat(8)0.11%
Revenue beat(12)3
Avg Revenue beat(12)-2.47%
Revenue beat(16)4
Avg Revenue beat(16)-2.8%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 542 | ||
| Fwd PE | 44.28 | ||
| P/S | 4.52 | ||
| P/FCF | 101.94 | ||
| P/OCF | 99.2 | ||
| P/B | 12.05 | ||
| P/tB | 12.19 | ||
| EV/EBITDA | 295.93 |
EPS(TTM)0.01
EY0.18%
EPS(NY)0.12
Fwd EY2.26%
FCF(TTM)0.05
FCFY0.98%
OCF(TTM)0.05
OCFY1.01%
SpS1.2
BVpS0.45
TBVpS0.44
PEG (NY)3.42
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.32% | ||
| ROCE | 1.15% | ||
| ROIC | 0.91% | ||
| ROICexc | 5.37% | ||
| ROICexgc | 5.71% | ||
| OM | 0.49% | ||
| PM (TTM) | 1.62% | ||
| GM | 61.45% | ||
| FCFM | 4.43% |
ROA(3y)-28.83%
ROA(5y)-43.66%
ROE(3y)-53.52%
ROE(5y)-87.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.69%
GM growth 5Y3.61%
F-Score8
Asset Turnover1.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 13.29% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 323.49% | ||
| Profit Quality | 273.47% | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.35 | ||
| Altman-Z | 8.91 |
F-Score8
WACC11.41%
ROIC/WACC0.08
Cap/Depr(3y)27.38%
Cap/Depr(5y)33.8%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y158.29%
EPS Next 2Y93.61%
EPS Next 3Y64.82%
EPS Next 5YN/A
Revenue 1Y (TTM)9.94%
Revenue growth 3Y12.14%
Revenue growth 5Y21.5%
Sales Q2Q%31.21%
Revenue Next Year16.58%
Revenue Next 2Y18.63%
Revenue Next 3Y17.67%
Revenue Next 5YN/A
EBIT growth 1Y106.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year201.26%
EBIT Next 3Y68.25%
EBIT Next 5YN/A
FCF growth 1Y120.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y121.17%
OCF growth 3YN/A
OCF growth 5YN/A